"Die Klinik für Medizinsche Onkologie und Hämatologie am USZ Campus ist spezialisiert auf die Diagnostik und Behandlung von Tumorerkrankungen aller Organsysteme. Ebenso diagnostizieren und behandeln die Klinik gutartige Veränderungen des Blutes und des Blutgerinnungssystems. Dank moderner Analysetechnik können wir präzise Diagnosen erstellen und personalisierte Therapien anbieten."

During the past decade, UniversitätsSpital Zürich; Zentrum für Hämatologie und Onkologie, Klinik für Onkologie conducted 18 clinical trials. In the 10-year time frame, 18 clinical trials started and 12 clinical trials were completed, i.e. on average, 66.7% percent of trials that started reached the finish line to date. In the past 5 years, 8 clinical trials started and 5 clinical trials were completed. i.e. 62.5% of trials that started reached the finish line.

Out of the total clinical trials conducted in "UniversitätsSpital Zürich; Zentrum für Hämatologie und Onkologie, Klinik für Onkologie" #1 sponsor was "Hoffmann-La Roche" with 19 trials, followed by "Gilead Sciences" with 2 trials sponsored, "Alliance Foundation Trials, LLC." with 1 trials sponsored, "Celgene" with 1 trials sponsored and "Celgene Corporation" with 1 trials sponsored. Other sponsors include -5 different institutions and companies that sponsored additional 5 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "UniversitätsSpital Zürich; Zentrum für Hämatologie und Onkologie, Klinik für Onkologie" #1 collaborator was "AbbVie" with 1 trials as a collaborator, "Austrian Breast & Colorectal Cancer Study Group" with 1 trials as a collaborator, "Breast International Group" with 1 trials as a collaborator, "Everest Medicines" with 1 trials as a collaborator and "Fondazione Italiana Linfomi ONLUS" with 1 trials as a collaborator. Other collaborators include 1 different institutions and companies that were collaborators in the rest 11 trials.

According to Clinical.Site data, the most researched conditions in "UniversitätsSpital Zürich; Zentrum für Hämatologie und Onkologie, Klinik für Onkologie" are "Non-Small Cell Lung Cancer" (3 trials), "Myelodysplastic Syndromes" (2 trials), "Non-Hodgkin's Lymphoma" (2 trials), "Adenocarcinoma" (1 trials) and "B-cell Lymphoma" (1 trials). Many other conditions were trialed in "UniversitätsSpital Zürich; Zentrum für Hämatologie und Onkologie, Klinik für Onkologie" in a lesser frequency.

Most popular intervention types in "UniversitätsSpital Zürich; Zentrum für Hämatologie und Onkologie, Klinik für Onkologie" are "Drug" (24 trials), "Biological" (2 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "Atezolizumab" (8 trials), "Carboplatin" (6 trials), "Cisplatin" (5 trials), "Paclitaxel" (5 trials) and "Gemcitabine" (4 trials). Other intervention names were less common.

The vast majority of trials in "UniversitätsSpital Zürich; Zentrum für Hämatologie und Onkologie, Klinik für Onkologie" are 23 trials for "All" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "UniversitätsSpital Zürich; Zentrum für Hämatologie und Onkologie, Klinik für Onkologie". undefined are not yet recruiting, 4 are recruiting, 8 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 9 completed trials in UniversitätsSpital Zürich; Zentrum für Hämatologie und Onkologie, Klinik für Onkologie, undefined suspended trials, and 3 terminated clinical trials to date.

Out of the total trials that were conducted in UniversitätsSpital Zürich; Zentrum für Hämatologie und Onkologie, Klinik für Onkologie, 1 "Phase 1" clinical trials were conducted, 6 "Phase 2" clinical trials and 17 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 0 trials that are defined as “Not Applicable".